TOKYO, September 3, 2024 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) successfully priced a dual-tranche of series 5th and 6th JPY denominated unsecured bonds (”the Bonds”) as below. The issuance of the Bonds is intended to partially repay and redeem short-term fundings.
| 1. Name of the Bonds | Astellas Series 5 Unsecured Bonds (Subject to a limited inter-bond pari passu clause) | Astellas Series 6 Unsecured Bonds (Subject to a limited inter-bond pari passu clause) |
| 2. Maturity | 5 years | 7 years |
| 3. Issue amount | JPY 80 billion | JPY 20 billion |
| 4. Denomination of each bond | JPY 100 million | |
| 5. Interest rate | 0.870% per annum | 1.038% per annum |
| 6. Issue price | 100.00% of the principal amount | |
| 7. Redemption price | 100.00% of the principal amount | |
| 8. Redemption method | Bullet Maturity Date: September 7, 2029 | Bullet Maturity Date: September 9, 2031 |
| 9. Interest payment dates | 9 of September and March for each year (Initial interest payment date: March 9, 2025) | |
| 10. Method of offering | Public offering | |
| 11. Pricing date | September 3, 2024 | |
| 12. Issue date | September 9, 2024 | |
| 13. Collateral and guarantees | The Bonds are not secured by any collateral or guarantees, and no assets have been retained specifically to secure them | |
| 14. Financial clauses | The Bonds carry a negative pledge clause (limited inter-bond pari passu clause) | |
| 15. Lead managers | Mizuho Securities Co., Ltd., Nomura Securities Co., Ltd., SMBC Nikko Securities Inc. and Goldman Sachs Japan Co., Ltd. | |
| 16. Fiscal agent | Sumitomo Mitsui Banking Corporation | |
| 17. Bond rating | AA (Rating and Investment Information, Inc.） | |
About Astellas
Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+® healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into VALUE for patients. For more information, please visit our website at https://www.astellas.com/en.
Cautionary Notes
In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management’s current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas’ intellectual property rights by third parties.
Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.
This press release is not an offer of securities for sale in the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or any state securities laws of the United States, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements under the Securities Act and applicable state securities laws of the United States.
Click below for a copy of the full press release
